Tislelizumab,Sorafenib
BeiGene,bayer,novartis
['tislelizumab', 'beigene']
beigene announces data presentations at esmo 2022 including late-breaking oral presentation for tislelizumab in first-line unresectable hepatocellular cancer - 
MD MSC CPDS https://t.co/kePCRsvthW  https://t.co/t7oxnCDRg8  #cardiology  #AI #informatics #healthcare #innovation #entrepreneur RSS feeds